Pfizer Faces Florida Lawsuit Over Vaccine Marketing as Eczema Drug Shows Promising Phase 2 Results
Pfizer announced positive Phase 2 data for its eczema antibody tilrekimig on the same day Florida filed suit alleging the company misled consumers about COVID-19 vaccine safety and risks. The lawsuit seeks injunctions, per-violation penalties, and profit recovery from the company's estimated $80 billion in vaccine sales, though Pfizer maintains the allegations lack merit and cites federal liability protections. The COVID vaccine franchise itself is contracting sharply, declining from $11 billion in 2024 to an expected $4 billion in 2026.
Pfizer's COVID-19 vaccine revenue has contracted dramatically over three years, falling from $11 billion in 2024 to a projected $4 billion by 2026—a decline that substantially narrows the financial exposure from Florida's lawsuit. The state's complaint seeks per-violation penalties under its consumer protection statute, though the ultimate cost remains uncertain pending discovery. Federal courts have previously shielded pandemic products from liability under the PREP Act, creating legal uncertainty about whether state-level claims will survive.
Tilrekimig's Phase 2 results suggest moderate efficacy in treating moderate-to-severe eczema, with the 200 mg dose achieving a 61% response rate versus 9% on placebo. The compound will compete directly with Dupixent in ongoing Phase 3 trials but enters a market where Pfizer already markets an approved oral competitor, positioning the asset as a portfolio extension rather than breakthrough therapy.
The lawsuit and revenue decline raise questions about market confidence in pandemic-era pharmaceutical products and litigation risk for vaccine manufacturers. If courts permit state-level consumer protection claims to proceed despite federal immunity provisions, other pharmaceutical companies could face similar challenges, potentially affecting future public health response investments. Conversely, sustained vaccine skepticism and declining demand may reduce both commercial opportunity and legal exposure as the franchise normalizes to endemic levels.